News

First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/26/2024

Stephanie Holland ;

According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...

According to results from the...

07/26/2024

Oncology

Conference Coverage

Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma

06/20/2024

Stephanie Holland

The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.

The addition of low-dose...

06/20/2024

Oncology

Conference Coverage

Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma

06/20/2024

Stephanie Holland

The addition of low-dose...

06/20/2024

Oncology

News

FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors

06/14/2024

Stephanie Holland

Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.

Based on results from the phase...

06/14/2024

Oncology

Conference Coverage

Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

06/11/2024

Stephanie Holland

According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.

According to updated results...

06/11/2024

Oncology

Conference Coverage

Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

06/11/2024

Stephanie Holland

According to updated results...

06/11/2024

Oncology

News

Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma

05/10/2024

Stephanie Holland

Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.

Results from a prospective,...

05/10/2024

Oncology

News

Radiotherapy Alone After Chemotherapy Induction for Patients With Nasopharyngeal Carcinoma

02/23/2024

Allison Casey

According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.

According to results from a...

02/23/2024

Oncology

News

Benefit From Postoperative Radiotherapy Improves With Increasing Tumor Size Among Patients with Oral Cavity Squamous Cell Carcinoma

02/13/2024

Allison Casey

According to a retrospective analysis, postoperative radiotherapy was associated with improved overall survival among patients with pT4aN0 oral cavity squamous cell carcinoma, and the relative survival benefit improved with increasing tumor...

According to a retrospective...

02/13/2024

Oncology

News

Streptococcus salivarius K12 Probiotic Reduced Severe Radiation-Associated Oral Mucositis Among Patients With Head and Neck Cancer

02/08/2024

Allison Casey

In this prospective, randomized, double-blind clinical trial, S. salivarius K12 reduced the incidence, onset, and duration of severe oral mucositis among patients undergoing radiotherapy for head and neck cancer.

In this prospective, randomized,...

02/08/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology